Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Allergan (AGN) upgraded to Buy from Neutral at Mizuho with analyst Irina Koffler saying she views Allergan's risk/reward more favorably following the company's "strong" beat and raise quarter and the delayed introduction of Restasis generics. 2. Pacira (PCRX) upgraded to Buy from Hold at Needham with analyst Serge Belanger citing "strong" Q2 performance of Exparel, where sales growth is accelerating while the company engages more of the anesthesiologist community. 3. Entergy (ETR) upgraded to Buy from Neutral at UBS with analyst Daniel Ford saying the stock no longer warrants a discount associated with nuclear decommissioning and operating performance risk. 4. Eversource (ES) upgraded to Neutral from Underperform at BofA/Merrill with analyst Julien Dumoulin-Smith saying the story has been de-risked with no major capex projects left. 5. TripAdvisor (TRIP) upgraded to Hold from Underperform at Needham with analyst Laura Martin saying while the company's pivot to competing as an online travel agent has failed, its focus to grow its non-hotel businesses is a "higher ROI idea." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Wells Fargo raised the firm's price target on Entergy to $122 from $115 and keeps an Overweight rating on the shares. The firm thinks recent positive regulatory developments plus Entergy's compelling long-term load growth outlook warrant a price to earnings multiple re-rating.

"We made very important regulatory progress in recent weeks that will deliver meaningful value for customers and provide certainty for all stakeholders," said Drew Marsh, Entergy chair and CEO. "We remain squarely on track with clear line of sight to achieve our commitments in 2024 and beyond."